Meningococcal Polysaccharide Vaccine (Subcutaneous Route)

3 imperatives to transform health care in America. You're invited to watch it live

Free

E-newsletter

Subscribe to Housecall

Our weekly general interest
e-newsletter keeps you up to date on a wide variety of health topics.

Sign up now

Meningococcal Polysaccharide Vaccine (Subcutaneous Route)

Drug Information provided by: Micromedex

US Brand Names

  • Menomune-A/C/Y/W-135

Description

Meningococcal polysaccharide vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.

The following information applies only to the meningococcal vaccine used for meningococcal bacteria Groups A, C, Y, and W-135. These groups cause approximately 50% of meningococcal meningitis cases in the U.S. The vaccine will not protect against infection caused by other meningococcal bacteria groups, such as Group B.

Meningococcal infection can cause life-threatening illnesses, such as meningococcal meningitis, which affects the brain, and meningococcemia, which affects the blood. Some persons with meningococcal meningitis and/or meningococcemia also may die. These diseases are more likely to occur in young children and in persons with certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.

Immunization against meningococcal disease is recommended for persons 2 years of age or older who are at risk of getting the disease because:

  • they have certain diseases or conditions that make them more susceptible to a meningococcal infection or more likely to develop serious problems from a meningococcal infection.
  • they are living in, working in, or visiting an area where there is a strong possibility of contracting meningococcal disease.

Usually a person needs to receive meningococcal vaccine only once. However, additional injections may be needed for young children who remain at high risk for meningococcal disease.

Meningococcal polysaccharide vaccine is to be administered only by or under the supervision of your doctor or other health care professional.

Before Using
DR600889 Portions of this document last updated: Nov. 1, 2011

Source: Drug Information provided by: Micromedex

Copyright © 2013 Thomson Healthcare Inc. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.

Advertisement


Text Size: smaller largerlarger